gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia.
gamma-Aminobutyric acid (Gaba) has been shown to influence dopamine activity in the brain. The author suggests that Gaba could be involved in the hypothesized dopamine hyperactivity in schizophrenia. He discusses pharmacological interventions that may raise Gaba-mediated function in the brain and states that further development of Gaba analogues seems clearly indicated. It is conceivable, he concludes, that these compounds could enhance the antipsychotic activity of dopamine receptor blockers, which could lead to the use of lower doses and therefore fewer extrapyramidal side effects.
D000613:Aminobutyrates / Q000502:physiology*; D000625:Aminooxyacetic Acid / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism; D003523:Cycloserine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology*; D018756:GABA Antagonists; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects; D011955:Receptors, Drug / Q000187:drug effects; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use
D000613:Aminobutyrates; D018756:GABA Antagonists; D008996:Monoamine Oxidase Inhibitors; D011954:Receptors, Dopamine; D011955:Receptors, Drug; D000625:Aminooxyacetic Acid; D005680:gamma-Aminobutyric Acid; D003523:Cycloserine; D004298:Dopamine